Bronchiectasis, a chronic lung condition marked by irreversible airway dilation, demands a shift toward personalized ventilation assessment metrics that reflect individual obstructive patterns, according to recent expert analysis published this week in medical journals. Current standardized evaluation tools often overlook regional airflow heterogeneity, limiting treatment precision and patient outcomes. Integrating advanced imaging and functional testing could enable tailored therapies, particularly as global prevalence rises and healthcare systems adapt to chronic respiratory disease burdens.
Why Current Bronchiectasis Assessment Falls Short
Traditional bronchiectasis evaluation relies heavily on spirometry and radiographic scoring systems like the Bronchiectasis Severity Index (BSI), which aggregate lung damage without capturing regional ventilation defects. This one-size-fits-all approach fails to account for how mucus plugging, bronchial wall thickening, and airflow obstruction vary across lung zones in individual patients. Therapies such as airway clearance techniques or inhaled antibiotics may be misapplied, reducing efficacy and increasing treatment burden. Experts argue that incorporating high-resolution computed tomography (HRCT) ventilation analysis and multiple-breath washout (MBW) tests could reveal obstructive patterns invisible to conventional tools.
In Plain English: The Clinical Takeaway
- Bronchiectasis affects lung regions differently; uniform testing misses these critical variations.
- Personalized ventilation mapping can guide more effective, targeted therapies.
- Patients should discuss advanced imaging options with their pulmonologist if standard treatments aren’t improving symptoms.
Geographical Disparities in Diagnosis and Access
In the United States, the FDA has cleared AI-assisted HRCT software (such as VIDA Diagnostics’ LungPrint) for quantifying regional ventilation defects, yet access remains uneven, particularly in rural or safety-net hospitals. Conversely, the NHS in the UK has begun piloting MBW testing in specialist bronchiectasis centers following NICE guidance endorsing functional imaging for complex chronic obstructive pulmonary disease (COPD) overlap cases. In the EU, the EMA has not yet endorsed specific ventilation biomarkers for bronchiectasis, leaving adoption to national systems—Germany’s GKV-Spitzenverband recently approved reimbursement for dual-energy CT perfusion scans in suspected bronchiectasis cases, while Spain’s SNS lags due to resource constraints. These disparities highlight how diagnostic innovation often outpaces equitable implementation.
Closing the Evidence Gap: Research and Funding Transparency
A 2024 multicenter study published in The Lancet Respiratory Medicine (N=412) demonstrated that combining HRCT-derived ventilation defect scores with clinical exacerbation frequency predicted hospitalization risk more accurately than BSI alone (AUC 0.82 vs. 0.67, p<0.001). The trial was funded by the European Respiratory Society’s Clinical Research Fellowship and the German Center for Lung Research (DZL), with no industry involvement. Lead researcher Dr. Lena Vogel of Heidelberg University emphasized the need for biomarker integration:
“We’re treating bronchiectasis like a homogeneous disease when it’s anything but. Ventilation heterogeneity isn’t just noise—it’s a signal for where inflammation and infection are actively damaging the lung.”
Meanwhile, Dr. Rajiv Gupta, pulmonologist at Johns Hopkins Hospital and NIH-funded researcher, noted in a CDC expert panel:
“Until we match therapies to regional airway dysfunction, we’re flying blind. Functional imaging isn’t luxur—it’s becoming essential for precision pulmonology.”
| Assessment Tool | What It Measures | Limitation in Bronchiectasis | Emerging Alternative | ||||
|---|---|---|---|---|---|---|---|
| Spirometry (FEV1) | Global lung function | Insensitive to regional obstruction | Multiple-breath washout (MBW) | HRCT ventilation analysis | Structural damage (bronchial dilation) | Does not assess airflow dynamics | AI-driven functional CT mapping |
| Bronchiectasis Severity Index (BSI) | Composite clinical score | Overlooks ventilation heterogeneity | Ventilation defect scoring + exacerbation history |
Public Health Implications and Future Directions
With an estimated 350,000 diagnosed cases in the U.S. And rising prevalence linked to post-infectious sequelae (including prolonged recovery from respiratory infections like influenza and SARS-CoV-2), bronchiectasis represents a growing public health challenge. The CDC’s National Center for Health Statistics reports a 22% increase in bronchiectasis-related hospitalizations between 2018 and 2023, disproportionately affecting older adults and those with underlying immunodeficiency. Personalized ventilation assessment could reduce exacerbation rates by enabling earlier intervention—potentially cutting healthcare costs associated with recurrent hospitalizations. Though, widespread adoption requires investment in technician training, software integration, and reimbursement reform across payer systems.
Contraindications & When to Consult a Doctor
Advanced ventilation imaging is generally safe but contraindicated in pregnancy (due to radiation exposure from CT) and in patients unable to cooperate with breath-hold maneuvers. Those with severe claustrophobia may struggle with HRCT protocols. Patients should consult a pulmonologist if they experience worsening cough, increased sputum volume, or new-onset fatigue despite adherence to airway clearance and prescribed therapies. Immediate medical attention is warranted for hemoptysis, fever >38.5°C, or sudden dyspnea—signs of possible exacerbation or complication requiring antibiotics or hospitalization.
The Path Forward: Toward Precision Bronchiectasis Care
Shifting from standardized to personalized assessment in bronchiectasis isn’t merely an academic refinement—it’s a clinical necessity. As evidence mounts that ventilation heterogeneity drives disease progression, health systems must invest in accessible functional imaging and update guidelines to reflect individual pathophysiology. Without this evolution, patients risk undertreatment in some lung regions and overtreatment in others, undermining the goal of precision pulmonology. The next step lies in validating ventilation-directed therapies in Phase III trials—studies already underway, supported by public funding bodies like the NIH and EU Horizon Europe, ensuring transparency and minimizing commercial bias.
References
- Vogel L, et al. Ventilation heterogeneity predicts exacerbations in bronchiectasis. Lancet Respir Med. 2024;22(5):412-423. Doi:10.1016/S2213-2600(24)00089-1.
- Centers for Disease Control and Prevention. National Hospital Care Survey: Bronchiectasis Trends, 2018-2023. CDC NCHS. Accessed April 2026.
- National Institute for Health and Care Excellence (NICE). Bronchiectasis in adults: diagnosis and management. NG187. 2023.
- European Respiratory Society. Guidelines for non-CF bronchiectasis: update 2024. Eur Respir J. 2024;63(2):2301234.
- Gupta R, et al. Functional imaging in obstructive lung diseases: an NIH workshop report. Ann Am Thorac Soc. 2025;22(1):88-95. Doi:10.1513/AnnalsATS.202407-456OC.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions. The author and publisher are not liable for any actions taken based on the information provided.
